Leland Stanford Junior University

Joslin Diabetes Center, Inc.

Children's Hospital Boston

Children's Medical Center Corporation

U.S. Government Represented by the Department of Veteran Affairs

Atul J Butte

C Ronald Kahn

Yu-Hua Tseng

Li Li

Minnie M Sarwal

Purvesh Khatri

Joel T Dudley

Tara Sigdel

Wenzhong Xiao

Amit Kaushal

Mark M Davis

Michael P Snyder

Shai S Shen-Orr

Konrad Karczewski

David Furman

Brian A Kidd

Alexander A Morgan

Eurie Hong

Alan Boyle

J Michael Cherry

Julie Park

Mazen Nasrallah

Keiichi Kodama

Peter M Marinkovich

Carl Gustaf Maarten Winge

Ronald C Kahn

Ronald Kahn

Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

Protein and gene biomarkers for rejection of organ transplants

Embodiments of the present invention provide diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on a combination of such markers obtained from various analyzes, primarily from blood, testing immune function including the analysis of immune cell subset frequencies, gene expression, cytokine and chemokine levels, and signaling responses to stimulation with cytokines ('cytokine response'). Particular combinations of markers can predict with high accuracy whether an individual will respond to active vaccination and become protected against recurring diseases.

Method of assaying an individual for immune impairment

Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Method and system for the use of biomarkers for regulatory dysfunction in disease

Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.

Methods and compositions for modulating adipocyte function

Methods and systems are provided for the computation and display of an individual's personalized health risk based on the genome sequence of the individual, known etiological interactions between diseases for which the individual is determined to have genetic risk factors, and environmental etiological factors associated with the same diseases that represent potentially modifiable disease risk modifiers.

Method and system for computing and integrating genetic and environmental health risks for a personal genome

Growing community of inventors

Menlo Park, CA, United States of America

Atul J Butte